Avoro Capital Advisors’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

Avoro Capital Advisors’s Portfolio BLCM Stock Details BLCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-12,500	Closed	-$1.54M	–	51
2017 Q1	$1.54M	Buy	+12,500	New	+$1.64M	0.2%	39
2015 Q3	–	Sell	-26,252	Closed	-$5.58M	–	40
2015 Q2	$5.58M	Sell	26,252 -21,250	-45%	-$5.21M	1.54%	19
2015 Q1	$11M	Buy	47,502 +25,502	+116%	+$6.17M	4.22%	6
2014 Q4	$5.07M	Buy	+22,000	New	+$4.72M	3.43%	10

Other funds holding BLCM

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Avoro Capital Advisors's BLCM Position: Q2 2017 in Review

Avoro Capital Advisors sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q2 2017, closing a stake of 12,500 shares — an estimated $1.54M sold.

Avoro Capital Advisors first reported a position in BLCM in Q4 2014 and held it in 4 quarters. The position peaked at $11M in Q1 2015. 84 funds tracked by Wall St. Rank hold BLCM as of Q2 2017.

Avoro Capital Advisors reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q2 2017 after selling out during the quarter.
Avoro Capital Advisors sold 12,500 Bellicum Pharmaceuticals, Inc. shares in Q2 2017, an estimated $1.54M.
Avoro Capital Advisors first reported a position in Bellicum Pharmaceuticals, Inc. in Q4 2014 and held it in 4 quarters.
Avoro Capital Advisors's Bellicum Pharmaceuticals, Inc. position peaked at $11M in Q1 2015.
84 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q2 2017.

Based on Avoro Capital Advisors's 13F filing for Q2 2017, filed 14 Aug 2017.